ARTICLE | Clinical News
Arrowhead's third-generation RNAi shows initial efficacy against HBV
September 14, 2018 3:19 PM UTC
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) reported initial data showing that monthly doses of its third-generation RNAi therapy ARO-HBV reduced circulating hepatitis B surface antigen (HBsAg) levels in a broad population of patients with chronic HBV infection.
The data were from eight patients that received three monthly subcutaneous doses of ARO-HBV in the lowest two dose cohorts of the Phase I/II AROHBV1001 trial. The cohorts included both hepatitis B e antigen (HBeAg)-positive patients and harder to treat HBeAg-negative patients, irrespective of prior treatment with nucleoside/nucleotide viral replication inhibitors (NUCs)...
BCIQ Company Profiles